Academic literature on the topic 'Pharmacoeconomics; Decision making'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmacoeconomics; Decision making.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pharmacoeconomics; Decision making"
Sanchez, Lisa A. "Pharmacoeconomics and Formulary Decision Making." PharmacoEconomics 9, Supplement 1 (1996): 16–25. http://dx.doi.org/10.2165/00019053-199600091-00005.
Full textNuijten, Mark JC. "Pharmacoeconomics in European Decision-Making." Value in Health 2, no. 5 (September 1999): 319–22. http://dx.doi.org/10.1046/j.1524-4733.1999.25005.x.
Full textRawlins, Michael, David Barnett, and Andrew Stevens. "Pharmacoeconomics: NICE's approach to decision-making." British Journal of Clinical Pharmacology 70, no. 3 (November 20, 2009): 346–49. http://dx.doi.org/10.1111/j.1365-2125.2009.03589.x.
Full textBeltz, Susan E., and Gary C. Yee. "Pharmacoeconomics of Cancer Therapy." Cancer Control 5, no. 5 (September 1998): 415–24. http://dx.doi.org/10.1177/107327489800500504.
Full textBala, MV, and GA Zarkin. "WMM3: MODELING SEQUENTIAL DECISION-MAKING IN PHARMACOECONOMICS." Value in Health 2, no. 3 (May 1999): 233. http://dx.doi.org/10.1016/s1098-3015(11)71092-0.
Full textArenas-Guzman, R., A. Tosti, R. Hay, and E. Haneke. "Pharmacoeconomics - an aid to better decision-making." Journal of the European Academy of Dermatology and Venereology 19, s1 (September 2005): 34–39. http://dx.doi.org/10.1111/j.1468-3083.2005.01285.x.
Full textLi, Hai-tao, Ai-xia Ma, Hong-chao Li, and Shi-xue Li. "Pharmacoeconomics in Healthcare Decision Making in China." Pharmaceutical Medicine 23, no. 5-6 (October 2009): 279–82. http://dx.doi.org/10.1007/bf03256782.
Full textYagudina, R. I., V. G. Serpik, and A. Yu Kulikov. "Pharmacoeconomics for the Health Care Managers: decision-making algorithm based on pharmacoeconomic assessments." Pharmacoeconomics: theory and practice 2, no. 1 (March 15, 2014): 13–20. http://dx.doi.org/10.30809/phe.1.2014.47.
Full textFranic, Duska. "Pharmacoeconomics of key importance in formulary decision-making." PharmacoResources 23, no. 1 (February 1995): 3–4. http://dx.doi.org/10.1007/bf03309495.
Full textvan Luijn, Johan C. F. "Is There a Role for Pharmacoeconomics in Decision Making?" PharmacoEconomics 30, no. 10 (October 2012): 979. http://dx.doi.org/10.2165/11633680-000000000-00000.
Full textDissertations / Theses on the topic "Pharmacoeconomics; Decision making"
Briggs, Andrew H. "Uncertainty in the cost-effectiveness of health care interventions." Thesis, University of Oxford, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.299755.
Full textSarnowski, Jeff J. "Decision-Making Associated with Drug Candidates in the Research and Development (R&D) Pipeline." The University of Arizona, 2006. http://hdl.handle.net/10150/624606.
Full textObjectives: To investigate the types of information and resources either used or required for the management of products in the pipeline as perceived by decision-makers in the biotechnology and pharmaceutical (B&P) industries. More specifically, the objectives are to ascertain the strategic use of pharmacoeconomic (PE), financial, and decision- making tools and financing requirements amongst pipeline candidates. Methods: A study-specific survey instrument was used for the project. In detail, this survey is based upon the use of financial, PE, and decision-making tools for drug product development. Approximately 396 B&P firms were surveyed via postal mail, wherein the primary contact was the Chief Financial Officer (CFO). If the CFO was not listed on the firm’s website, the survey will be addressed to the Business and Development Officer (BDO) or Chief Executive Officer (CEO). The companies’ information will be identified by use of publicly-available databases. A modified form of a total survey design will be used for the postal mailings, including one initial mailing with a cover letter and survey, a follow-up reminder postcard, a second cover letter and survey for non-responders, and a final follow-up reminder postcard then after. Results: Survey instruments were completed by 20 firms, with 5 of them from public firms and 15 from the private sector. Capital and regulatory requirements and investor expectations are the most important factors considered during early and late phase clinical trials. Net present value (NPV) and internal rate of return (IRR) are the most commonly used financial analytic tools used for making research and development (R&D) decisions. PE are reported to be first used during all clinical phases prior to Food and Drug Administration (FDA) approval, and most drug candidates undergo formal PE evaluations. PE is also used in various areas of R&D and marketing components, such as licensing and go/no-go decisions. Capital/securities markets and venture capital (VC) are the primary sources of capital used in the development of a new drug. VC is important during all phases of R&D and numerous VC firms get involved. B&P firms disagree that VC companies should be involved with the managerial roles of the firm. Conclusions: It has been determined that the strategic use of PE, financial and decision-making tools, and capital requirements amongst pipeline candidates are important during all phases of R&D.
Khalil, Mohamed. "Pharmacoeconomic evaluation in Egypt and its role in the medicine reimbursement." University of the Western Cape, 2018. http://hdl.handle.net/11394/6385.
Full textAim: The purpose of this research was to assess the validity of pharmacoeconomic evaluation in Egypt three years after the guideline was issued and analyse challenges and opportunities for improvement. Objectives: To conduct a literature review of pricing, medicine reimbursement, and pharmacoeconomic evaluation. Examine, in conjunction with relevant stakeholders, the progress of the pharmacoeconomic evaluation. To present examples of pharmacoeconomic evaluation deployment. To propose recommendations on how to optimize the pharmacoeconomic implementation. Methods: A literature review and a qualitative research method that was conducted using a semi-structured interview with stakeholders of the reimbursement process in Egypt. In addition, examples were analysed to determine the impact of pharmacoeconomic methods on medicine reimbursement in Egypt. Results: The Egyptian Pharmacoeconomic Evaluation Unit was established in 2013, it supports various reimbursement decisions, especially for new technologies. The unit evaluations depended mainly on the available international data. However, fragmentation of the health care system in Egypt is a major obstacle to progress. The guidelines are still non-compulsory for implementation, and accordingly some reimbursement committees do not consider its evaluation in its decision making. Conclusion and Recommendations: The pharmacoeconomic evaluation has demonstrated a good start in Egypt. To gain the full benefit of pharmacoeconomic evaluation, authorities need to consider reducing the complexity of health care system, setting clear strategies, building capabilities to improve pharmacoeconomic awareness; endorsing risk sharing strategy and building a proper health related information system along with creation of full Health Technology Assessment program. The above-mentioned recommendations could be associated together under the Universal Health Coverage road map that Egypt committed to achieve by 2030.
Books on the topic "Pharmacoeconomics; Decision making"
Pharmacoeconomics: From theory to practice. Boca Raton: Taylor & Francis, 2010.
Find full textG, Arnold Renee J., ed. Pharmacoeconomics: From theory to practice. Boca Raton: Taylor & Francis, 2010.
Find full textG, Arnold Renee J., ed. Pharmacoeconomics: From theory to practice. Boca Raton: Taylor & Francis, 2010.
Find full textBook chapters on the topic "Pharmacoeconomics; Decision making"
"Computer-Aided Decision Making from Drug Discovery to Pharmacoeconomics." In Pharmacoeconomics, 223–40. CRC Press, 2016. http://dx.doi.org/10.1201/9781420084405-20.
Full textEkins, Sean, and Ren√©e Arnold. "Computer- Aided Decision Making from Drug Discovery to Pharmacoeconomics." In Pharmacoeconomics, 209–26. CRC Press, 2009. http://dx.doi.org/10.1201/9781420084405.ch15.
Full textPostma, Maarten J., and Gijs A. A. Hubben. "The Role of Pharmacoinformatics in Enhancing the Pharmacoeconomics Context of Decision Making." In Pharmacoinformatics and Drug Discovery Technologies, 44–52. IGI Global, 2012. http://dx.doi.org/10.4018/978-1-4666-0309-7.ch004.
Full text